Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 138-144

  Kousignian, I ^a,b   Launay, O ^c   Mayaud, C ^d   Rabaud, C ^e   Costagliola, D ^a,b,f   Abgrall, S ^a,b,g  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Pôle de Médecine ^*  (France)

^d HÔPITAL TENON   (France)

^e CHU NANCY BRABOIS   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g AVICENNE HOSPITAL   (France)

Author keywords

cART; Cohort study; HIV

Indexed keywords

COTRIMOXAZOLE; ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 77950355980     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp402     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
3. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 2000; 30 Suppl 2: S177-84.
4. Rousseau MN, Vergne L, Montes B et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 36-43. Erratum in: J Acquir Immune Defic Syndr 2001; 26: 395.
5. Race E, Dam E, Obry V et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13: 2061-8.
6. Van Vaerenbergh K, Van Laethem K, Albert J et al. Prevalence and characteristics of multinucleoside-resistant human immuno-deficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44: 2109-17.
7. Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65.
8. Department of Health and Human Services. FDA Approves Fuzeon. 13 March 2003. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125088.htm (October 2003, date last accessed).
9. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9: 1051-3.
10. Cohen CJ, Dusek A, Green J et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002; 16: 327-35.
11. Kilby JM, Lalezari JP, Eron JJ et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18: 685-93.
12. Lalezari JP, Eron JJ, Carlson M et al. A phase II clinical study of the longterm safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17: 691-8.
13. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
14. Wheeler DA, Lalezari J, Kilby M et al. Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment experienced HIV-1-infected patients. J Clin Virol 2004; 30: 183-90.
15. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
16. Nelson M, Arastéh K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-12.
17. Trottier B, Walmsley S, Reynes J et al. Safety of enfuvirtide in combination with an optimized background. J Acquir Immune Defic Syndr 2005; 40: 413-21.
18. French Hospital Database on HIV (FHDH). Available online at: www.ccde.fr (July 2007, date last accessed).
19. Tassie JM, Gasnault J, Bentata M et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 1999; 13: 1881-7.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
21. WHO. Manuel de la Classification Statistique Internationale des Maladies et des Problèmes de Santé Connexes, 10th révision. Geneva, Switzerland: WHO, 1993.
22. Barry P, Zetola N, Keruly JC et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20: 437-44.
23. Kohli R, Lo Y, Homel P et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV Epidemiologic Research (HER) study. Clin Infect Dis 2006; 43:90-8.
24. Sogaard OS, Lohse N, Gerstoft J et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47: 1345-53.
25. Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume II: The Design and Analysis of Cohort Studies. IARC Scientific Publications No. 82. Lyon, France: IARC, 1987; chapter 7, page 283.
26. Yéni P et le groupe d'experts sur l'infection par le VIH. Suivi de l'adulte infecté par le VIH. In: Prise en Charge Médicale des Personnes Infectées par le VIH. Rapport 2006. Paris, France: Flammarion Médecine-Sciences, 2006; 68-9.
27. Le Moing V, Rabaud C, Journot V et al. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med 2006; 7: 261-7.
28. Sullivan JH, Moore RD, Keruly JC et al. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Crit Care Med 2000; 162:64-7.